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ABSTRACT 
 
YINGQIU ZHOU: CHARACTERIZATION AND APPLICATIONS OF SINGLE-DOMAIN 
ANTIBODY MIMICS AGAINST ERBB3 
(Under the direction of Rihe Liu) 
 
As a member of EGFR family, ErbB3 is a critical heterodimerization partner of 
EGFR and ErbB2 in many EGFR- or ErbB2-driven cancers. As a ligand of ErbB3, 
heregulin β-1 (NRG1) induces the dimerization of ErbB3 with other ErbB family 
members and triggers downstream pathways. Using the directed protein evolution 
technique mRNA display, we successfully identified SDAHER3-A1 and SDAHER3-D5 that 
bind to ErbB3 with very high affinity and specificity in vitro and on cell surface. A 
biparatopic SDAHER3-D5A1 was constructed for improved biophysical properties and 
picomolar affinity (80.3 ± 20.3 pM) to ErbB3. SDAHER3-D5A1 binds to ErbB-expressing 
MCF7 cells with a binding affinity of 35.61 ± 17.07 nM. SDAHER3-D5A1 inhibits the 
NRG1-induced proliferation in a dose-dependent manner. SDAHER3-D5A1 is able to 
carry the conjugated AuNP to ErbB3-overexpressed cell and kill the cancer cell by 
hyperthermia treatment. Combined with Lapatinib, a kinase inhibitor, SDAHER3-D5A1 
showed improved efficiency in inhibiting the proliferation of cancer cells with ErbB2 and 
ErbB3 overexpressed. An examination of downstream signaling pathways suggested 
that SDAHER3-D5A1 significantly decreased NRG1-induced ErbB3-/Akt-/ERK- 
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phosphorylation and the combination with the drug further inhibits the phosphorylation. 
SDAHER3-D5A1-IRDye800 conjugates was synthesized and confirmed that SDAHER3-
D5A1 can be used to target ErbB3-overexpressed tumor xenograft models and may be 
very useful for imaging purpose.  
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CHAPTER 1 
Introduction 
 
Targeted Cancer Therapy 
Human cancer carries multiple mutations, including gene amplification, 
microsatellite instability, chromosomal aberration and aneuploidy1. Numerous studies 
have linked such mutations and aberrations with various types of cancers2, which 
provides some valid background for designing targeted agents for cancer treatment. 
Targeted cancer therapy uses molecules to interfere specific target that plays a critical 
role in cancer growth and progression. Some popular targets includes kinases, cancer 
stem cells, microenvironment and combining targeted therapy with chemotherapy and 
the agents can be small molecules, antibodies or antisense inhibitors3,4. Among these, 
kinases are important targets for oncology drug discovery.  
There are approximately 518 kinases encoded in human genome and many of 
them are involved in tumor proliferation and survival, such as ABL-fusion proteins, 
EGFR, KIT, PDGFR, FMS, VEGFR, FLT3, SRC-family (SFK) or cyclin-dependent 
kinases (CDKs)5. Common approaches include targeting mutations of kinases, inhibiting 
kinases, targeting kinases that are essential for tumor formation and maintenance in 
human body6. There are more than 150 drugs in clinical development that target 
kinases and many more in preclinical research7. Many of the 
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kinases inhibitors have already been approved by FDA and have reached the market for 
cancer treatment. From January 2012 to February 2015, there were 15 new small-
molecule kinase inhibitors approved by FDA8. Glivec (STI1571, imatinib) was the first 
kinase inhibitor approved by FDA to treat leukemia by targeting BCR-Abl9. Recent 
examples include Zydelig (Idelalisib), the first PI3K inhibitor, and Lenvima (Lenvatinib) 
targeting VEGFR family10–12. There have been great successes in kinases inhibitor 
discovery; however, there are growing concerns regarding the development of drug 
resistance. Usually, the targeted kinases are very important in cell metabolism survival 
and carries important functions. Therefore, the genetically unstable cancer cells may 
undergo compensation processes. Moreover, it may also contribute to the multiple 
binding surfaces or action through other mechanisms5.  For example, some imatinib-
resistant CML patients carry overexpressed BCR-ABL13. To overcome this problem, 
many preclinical studies tried to unveil drug-resistance mechanisms, improve the drug 
pharmacokinetic/pharmacodynamics properties, develop co-targeting strategies and 
develop new agents5.  
The ErbB family and cancer 
Tyrosine kinases are a subclass of protein kinases that transfer a phosphate 
group from ATP to another protein. Protein tyrosine kinases (PTK) can be categorized 
into two classes, receptor tyrosine kinases (RTK) and non-receptor tyrosine kinases. 
Receptor tyrosine kinases regulate many key functions of cells, such as cell growth, 
survival, organ morphogenesis, neovascularization, tissue repair and tissue 
regeneration14. They also play crucial roles in oncogenesis15. Human RTK has 20 
subfamilies. In general, growth factors can bind and activate RTKs, and form dimeric or 
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oligomeric complex. One RTK from the complex phosphorylates the neighboring 
tyrosine from another RTK. The phosphorylated tyrosine recruits the downstream 
signaling proteins later16. The ligand-binding induced dimerization activates multiple 
cytoplasmic signaling pathways, such as RAS/Raf – MAPK pathway, pI3K/Akt pathway 
and protein kinase C pathway4. The other mechanism of dimerization for most RTKs 
includes receptor-mediated or a combination of ligand-mediated and receptor mediated 
mode16. In normal cells, the activity of RTKs is strictly regulated. However, in many 
cancers, some RTKs are dysregulated or constitutively activated14. Thus, RTKs attract 
many attentions from researchers as promising therapeutic targets for cancer therapies.  
To become a targeted RTK for cancer treatment, the RTK itself usually is a major 
regulator of cancer survival and/or proliferation14. EGFR is one of the earliest 
discoveries in RTKs and related to cancer as an oncogene. In 1980s, the 
overexpression of EGFR was reported in many epithelial tumors, with several deletions 
and/or point mutations15. EGFR is one of the ErbB receptors. In the search of 
oncogenes, four ErbB family members were identified, EGFR (ErbB1, Her1), ErbB2 
(Her2, Neu), ErbB3 (Her3) and ErbB4 (Her4). Figure 1.1 illustrates the four family 
members and its corresponding growth factor group as ligands. As shown in the figure, 
ErbB2 has no known natural ligand while ErbB3 lacks protein kinase domain. The 
structure of ErbBs includes extracellular domain, trans-membrane segment and C-
terminal tail. The extracellular segment contains four domains (I-IV). Domains I and III 
involve in binding (except ErbB2, which lacks this two domains), while domain II is the 
site for dimerization. Therefore, ErbB2 prefers forming dimers with another ligand-bound 
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receptor17. As indicated above, ErbB3 is the only one in the family that does not contain 
kinase domain in its C-terminal tail18.  
Similar to other protein kinases, ErbB receptors are activated by forming homo-
/heterodimers. Dimerized receptors phosphorylate the C terminus and trigger the 
downstream signaling pathways. Table 1.1 shows the ErbB receptor dimers and their 
ligands. The dimerization of ErbB receptors suggest an effective approach to block 
ErbB-mediated transformations by identifying inhibitors disrupting the interactions19. 
The ErbB family involves in many important signaling pathways, as illustrated by Figure 
1.2. For example, ErbB2 and EGFR can stimulate signaling proteins and pathways, 
including MAPK, PI3K/Akt and mTOR pathways, Src kinase, and STAT transcription 
factors20. The dysregulation of ErbB signaling pathways, such as mutations and/or 
overexpression, occurs in various cancers. 
The overexpression, gene amplification or mutations of EGFR are found in many 
cancers, such as breast cancer, lung cancer, head and neck cancers, and highly 
expressed in brain tumors. EGFRvIII is the most common mutation of EGFR, which has 
been related to resistance to radiation therapy for cancer treatment21,22. The association 
between ErbB2 and breast cancers is well studied. Clinical trials implied that women 
with ErbB2-positive tumors usually have poorer prognosis23. Overexpression of ErbB2 is 
also very common in other types of cancers such as ovarian, lung, pancreas, colon, 
esophagus, prostate, endometrium, and cervix cancers22. Although ErbB3 is kinase 
defective, it can be phosphorylated by other receptors. It plays a major role in cell 
survival18 and is related to various types of cancers. The overexpression of ErbB3 has 
been observed in 20-30% of the invasive breast cancers24. The function and role of 
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ErbB3 in cancers are discussed in the later sections. ErbB4 is the least studied ErbB 
receptor in the family. Some reports suggested its prognostic value in breast cancer25,26. 
Overall, the ErbB receptor family plays an important role in cancer proliferation and 
progression.  
Targeting ErbB receptors for cancer treatment 
The ErbB receptors and its ligands locate in the extracellular domain. There are 
several approaches targeting ErbB receptors, directly targeting the receptor by 
monoclonal antibodies (mAbs) , synthetic small molecule tyrosine kinase inhibitors that 
inhibit the kinase domain of ErbB receptors and conjugating toxins with mABs18,22. ErbB 
receptors (except ErbB3) have inducible kinase activities at the C terminus and activate 
downstream pathways once activated. Even without bounded-ligand, overexpressed 
receptors may still have enhanced kinase activities. There are reversible and 
irreversible inhibitors that target the kinase domains of ErbB receptors. Reversible 
inhibitors compete with the binding ATPs; while irreversible inhibitors react with a 
cysteine residue within the ATP-binding pocket and block the kinase activity 
permanently19. mAbs usually target the extracellular domains of the ErbB receptors. 
Trastuzumab is the first mAb that targets ErbB2. It dramatically improve the progression 
and overall survival rate for ErbB2-positive breast cancer patients27. A third approach is 
to use antibody-drug conjugates (ADCs). Ado-trastuzumab emtansine is an approved 
antibody-drug conjugate targeting ErbB2. It contains ErbB2 targeting mAb trastuzumab, 
a stable thioether linker, and a derivative of toxin maytansine18. The antibody carries the 
toxin into the cell and the released toxin from the antibody kills the cell.  
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So far, FDA has approved six kinase inhibitors, five antibody drugs and one ADC 
targeting EGFR and/or ErbB2, as shown in Table 1.2. Some antibodies targeting ErbB3 
are in pre-clinical and clinical trials, including mAbs against ErbB3, bispecific mAbs 
against ErbB3. Many of the drugs are very successful in treating ErbB2 positive tumors 
and non-small cell lung cancer (NSCLC) patients. However, there are observations that 
some patients developed resistance to trastuzumab27 or only responded to Gefitinib or 
erlotinib for only 6-12 months28. Several mechanisms contribute to the resistance to 
ErbB related cancer therapies. Gefinitib and erlotinib target the EGFRs with functional 
mutations in the kinase domain of the C-terminus. During the treatment, the cancer cells 
may develop drug-sensitive mutations. Trastuzumab cannot block the signaling 
pathways of the cells that have autocrine EGFR activation or ligand-induced 
dimerization of ErbB2 and its partners. The drug resistance may also develop through 
activation of other RTKs or the loss of lipid phosphate PTEN, which is a negative 
regulator of PI3K17,18,28,29.  New therapeutic agents or drug combination may be use to 
overcome the issues with drug resistance.  
Targeting ErbB3 and combination therapies 
The role of ErbB3 in cancer development has been intensively studied in recent 
years. Structurally, it is very similar to other family members, except the impaired kinase 
domain in the C-terminus. The ligands for ErbB3 belong to NRG family, which contains 
an EGF like C-terminal region and varies in N-terminus30. ErbB3 serves as specialized 
allosteric activator and signaling substrate of EGFR, ErbB2 and ErbB431. In the 
presence of ErbB3 ligand, it promotes the kinase activity of its binding partners32. After 
dimerization, the dimerization partner phosphorylates the C-terminal tyrosine residues 
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of ErbB3, which can bind to SH2 or PTB binding proteins and trigger the downstream 
pathways later31. Thus, ErbB3 is a potential activator for PI3K/Akt/mTOR pathway 
through its tyrosine sites on C-terminus, as well as Ras/Raf/MAPK pathways33. The 
PI3K/Akt/mTOR pathway play important role in tumorigenesis and is considered a major 
driven factor in drug resistance of cancer treatment34. ErbB3 shows its significance in 
the ErbB2-driven tumors and the drug resistance by the upregulation of ErbB3. The 
upregulated ErbB3 then directly or indirectly activates the PI3K signaling pathway in 
those tumors35. ErbB3 contributes to the drug resistance to EGFR-targeted therapy by 
the gene amplification of MET36. The upregulation of ErbB3 also shows its connection to 
acquired resistance to RAF/MEK inhibitors in melanoma and thyroid carcinoma35.  
The overexpression of ErbB3 has been observed in primary cancers, including 
breast, ovarian, prostate, colon, pancreas, stomach, oral cavity and lung cancers30. 
There are direct and indirect strategies targeting ErbB3 for cancer treatment. The 
indirect strategies include targeting NRGs, PanHER inhibitors preventing the auto- and 
trans-phosphorylation of ErbB3 or targeting ErbB3 at transcriptional level37. As 
mentioned in the previous section, ErbB3 is the only member in the family that lacks 
functional kinase domain. Although some small molecule inhibitors were designed to 
target the ATP-binding region of ErbB338–40, the direct ErbB3 targeting strategy is by 
using monoclonal antibodies. Patritumab is the first human antibody targeting ErbB3, 
which inhibits the ligand-induced phosphorylation of ErbB3, and the downstream 
singling pathway of PI3K/Akt and MAPK/ERK41. MM-121 competes with NRG for ErbB3 
binding and inhibits the ligand-induced signaling pathway42. LJM716 keeps ErbB3 in an 
inactive conformation and inhibits ligand-dependent/ligand-independent activity of 
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ErbB343. Other antibodies may promote the degradation of ErbB3 or prevent the 
dimerization of ErbB2 and ErbB337. Considering the physiological role of ErbB3 in ErbB 
network and drug resistance, some bispecific mAbs are also under development or 
have already been in clinical trials44,45. Meanwhile, combination therapies of ErbB3 
antibodies and other drug agents or chemotherapies, also show some promising 
outcomes in clinical trials35,46.  
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Figure 1.1 ErbB family and the ligands, adapted47 
The ErbB family contains four receptors. All family members contains extracellular 
domain, transmembrane region and C-terminus kinase domain. However, ErbB2 does 
not have known ligand while the kinase activity of ErbB3 is impaired. 
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Figure 1.2 Signaling pathway of ErbB receptors, adapted from cellsignal.com 
 
The ErbB family members activate downstream signaling pathways through homo- or 
hetero-dimerization. The downstream signaling pathways include MAPK/ERK, 
PI3K/Akt/mTOR, and other important ones, which play important role in cancer 
proliferation, survival and apoptosis. 
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Table 1.1 ErbB receptor dimers and their ligands, adapted18 
Receptor 
dimers 
Ligands 
ErbB1-ErbB1 EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR (groups 1 and 2) 
ErbB1-ErbB2 EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR (groups 1 and 2) 
ErbB1-ErbB3 
EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR, Nrg-1, Nrg-2 (groups 
1, 2 and 3) 
ErbB1-ErbB4 
EGF, EPG, TGFα, AR, BTC, HB-EGF, EPR, Nrg-1, Nrg-2, Nrg-3, 
Nrg-4 (groups 1, 2, 3 and 4) 
ErbB2-ErbB2 None 
ErbB2-ErbB3 Nrg-1, Nrg-2 (group 3) 
ErbB3-ErbB3 Nrg-1, Nrg-2 (group 3) 
ErbB2-ErbB4 BTC, HB-EGF, EPR, Nrg-1, Nrg-2, Nrg-3, Nrg-4 (group 2, 3 and 4) 
ErbB3-ErbB4 BTC, HB-EGF, EPR, Nrg-1, Nrg-2, Nrg-3, Nrg-4 (group 2, 3 and 4) 
ErbB4-ErbB4 BTC, HB-EGF, EPR, Nrg-1, Nrg-2, Nrg-3, Nrg-4 (group 2, 3 and 4) 
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Table 1.2 FDA approved small molecule drugs and antibody drugs targeting 
EGFR and ErbB2 
 
Drug Company Target Year  
Small molecules 
Afatinib/Gilotrif® Boehringer Ingelheim EGFR 2013 
Erlotinib/Tarceva® Genentech/OSI EGFR 2004 
Gefitinib/Iressa® AstraZeneca EGFR 2003 
Lapatinib/Tykerb® GlaxoSmithKline EGFR/ErbB2 2007 
Vandetanib/Caprelsa® AstraZeneca 
EGFR/VEGFR/RET-
tyrosine kinases 
2011 
Osimertinib/Tagrisso® AstraZeneca EGFR 2015 
Antibody 
Necitumumab/Portrazza® Eli Lilly EGFR 2015 
Pertuzumab/Perjeta® Genentech ErbB2 2012 
Ado-trastuzumab 
emtansine/Kadcyla® 
Genentech ErbB2 2013 
Trastuzumab/Herceptin® Genentech ErbB2 1998 
Cetuximab/Erbitux® 
ImClone/Eli 
Lilly/Bristol-Myers 
Squibb 
EGFR 2004 
Panitumumab/Vectibix® Genentech EGFR 2006 
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Table 1.3  ErbB3 targeting antibodies in development and clinical trials37 
Names Binding Site Blocking NRG binding 
In clinical trials 
MM-121 (Seranbitumab)  Unknown Yes 
U3-1287 (Patritumab) Unknown Unknown 
LIM716 Between domains II-IV No 
AV-203 Unknown Yes 
REGN1400 Unknown Yes 
GSK2849330 Domain III Yes 
RG7116 (Lumretuzumab) Domain I Yes 
Under development 
TK-A3 and TK-A4 Domains II / Unknown Yes/Yes 
MP-RM-1 (EV-20) Unknown No 
9F7-F11 and 16D3-C1 Domain I / Domain I No/Yes 
NG33 Unknown Yes 
A5/F4 Domains I & III Yes 
Bispecific Abs in clinical trials 
Name Target 
MM-111 ErbB2 & ErbB3 
MEHD7945A (Duligotuzmab, RG7597) EGFR & ErbB3 
MM-141 IGF-IR & ErbB3 
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CHAPTER 2 
Characterization of the pre-selected single-domain antibody mimics against 
ErbB3 
 
Introduction 
Directed evolution is an effective approach to select or improve biomolecules 
with desired properties. The evolution of protein/peptides in vitro mimics the biological 
evolution. The steps includes diversify genetic codes, screen and identify the potential 
candidates48. The current methods for protein selection includes Yeast two-hybrid 
system, phase display, cell surface display and ribosome display49.  mRNA display 
covalently connect mRNA with its translated protein through puromycin analogue50. 
Different diversified libraries are used for laboratory evolution. Human fibronectin (FN3) 
is an extremely abundant extracellular protein that occurs in approximately 2% of all 
human proteins in cell surface receptors. The tenth type III domain of FN3 appears to 
be an ideal scaffold for the development of natural ligand competitors by using directed 
evolution, due to its small size (less than 10 kDa), CDR-like ligand binding surface 
loops, lack of disulfide bonds, high expression level in bacteria, exceptional 
thermostability (Tm ~90 °C), and little immunogenicity51,52. In the present study, we used 
mRNA display technique to select a fibronectin type III (FN3) domain-based library and 
identified proteins that can bind to ErbB3.  
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Two mRNA-display based selections were performed, as shown in Figure 2.1. 
For general elution approach, we directly collected the selected fusion molecules from  
the ErbB3-beads after washing. For the Ligand-specific approach, we performed 
competitive elution by using NRG β-1, which should elute fusion molecules that bind 
specifically to the NRG binding site on ErbB3. The recovery of the selected molecules 
was determined by the ratio of radioactivity from elution to that from total library used for 
selection. In general, the recovery was very low due to the high-diversity of the original 
library. After several rounds of selections, a significant increase in recovery indicated 
the successful enrichment of SDAHER3 sequences with desired features, as shown in 
Figure 2.2. This study focuses on protein identification and characterization from this 
selected library. 
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Materials and Methods 
Sequencing the selected FN3 library against ErbB3 
The gene coding selected FN3 molecules were sub-cloned into pJET1.2/blunt 
plasmid (Thermo Scientific). The resulting plasmids were transformed into DH5α 
Competent E. coli (New England BioLabs). Single clones were picked and grown in 96 
well plates with LB media at 37°C overnight. The cells were amplified with PCR. The 
PCR products were collected and got sequenced (Eton Bioscience Inc.). Unipro 
UGENE v1.10.1 and ClustalW2 were used for sequence alignment and analysis.  
Construction, expression and purification of soluble SDA molecules 
The coding genes of the selected SDAHER3s were amplified and assembled to a 
fusion gene through PCR using primers (5’-
GAGGATCCGTGTCTGATGTTCCGCGTGAT-3’, 5’-
GAGCGGCCGCTTACTTGTCGTCGTCGTCCTTGTAGT-3’). The generated products 
were firstly ligated to pJET1.2/blunt plasmid and then later ligated to the BamH I & Not I 
(New England BioLabs) sites of pET28b plasmid. The resulting plasmids were further 
confirmed by DNA sequencing (UNC genome analysis facility) and transformed to E.coli 
BL21 (DE3) competent cells (New England BioLabs). Cells were grown in LB media 
with kanamycin at 37 °C until OD ~0.6 (600nm) and then induced with 0.3 mM 
isopropyl-beta-D-thiogalactopyranoiside (IPTG) at 20 °C for 16 h. The purification 
process was performed as described in the previous work in our lab53. Each SDAHER3-
A1 and SDAHER3-D5 have two versions including one version with one cysteine in the C-
terminus. For protein labeling, the SDAHER3s (SDAHER3-A1-Cys, SDAHER3-D5-Cys) were 
first incubate with TCEP·HCl (Thermo Scientific) with 1:2 ratio, for 30min at room 
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temperature. A molar ratio of 1:10 was used to incubate the SDAs and Alexa-Fluor 555 
C2 maleimide (Life technologies) at 4 °C overnight. Illustra NAP-5 Columns (GE 
healthcare) were use remove the excessive dyes. The process of the purified SDAs 
(Wildtype-FN3) labeling with Alexa-Fluor Fluor 555 carboxylic acid, succinimidyle ester 
(Life technologies) was described in the previous work54. 
Kinetic binding analysis of SDAs 
ProteOn XPR36TM array system (Bio-Rad) was used for kinetic binding analysis 
of SDAHER3s. The soluble extracellular domain of human recombinant ErbB3 EDC-Fc 
and EGFR EDC-Fc were purchased from R&D Systems. SDAHER3 samples were 
prepared as described above. Each receptor was diluted with 10mM sodium-acetate 
buffer at pH 5. The immobilization of ErbB3 and EGFR were performed on a GLM 
sensor chip (Bio-Rad) through amine coupling approach55. Five different SDAHER3 
concentration (from 200nM to 12.5nM in two-fold dilution) were injected over the 
immobilized Fc-ErbB3 channel and EGFR channel. The dissociation constant (KD) were 
calculated by the software with 1:1 binding model.  
Cell culture 
ErbB3-positive ASPC1, MDA-MB-453 and ErbB3-negative MDA-MB-231, 
SKOV3 were obtained from UNC Tissue Culture Facility. Each cell line was cultured by 
serial passage with proper media in 5% CO2 incubator, at 37 °C. 
Confocal microscopy 
Each cell line (about 2 x 104) was plated on glass coverslides and grew in media 
overnight. The coverslides were washed with 1 x PBS twice before incubating with 
different concentration of Alexa-Fluor 555-labeled SDAHER3s for 30 min on ice, or for 2 h 
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at 37 °C. The coverslides were then washed with 1 x PBS for three times. The samples 
were examined with Zeiss LSM 700 confocal microscopy at UNC Microscopy Services 
Laboratory (MSL).  
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Result 
Pre-selected SDAs with distinct sequences shows good solubility and level of 
expression 
In this study, the FN3 scaffold-based SDAs that bind to the NRG1-binding site on 
ErbB3 were evolved from an mRNA-displayed human FN3 domain library with a 
diversity of 5×1013. Two different selections were performed, including the general 
elution and the ligand-specific elution approach. The selected library members were 
amplified and sequenced. With simple clustering approach, five classes of SDAHER3s 
with the following sequences were selected. The selected sequences were amplified 
and inserted into protein expression vectors containing His-tag for purification. All five 
proteins were expressed and purified. The expression level of most of the selected 
SDAHER3s were good and were soluble as well. Initial binding tests against ErbB3 were 
performed to exclude the weak binders and those with poor solubility (data not shown). 
Among the five sequences, SDAHER3-A1 was the dominant sequences (~50%) from the 
general elution approach after eight rounds of selection; while the sequence of 
SDAHER3-D5 presented in both of selections and was the major sequence in ligand-
specific elution approach after nine rounds of selection. Both the two SDAHER3s, 
SDAHER3-A1 and SDAHER3-D5, were selected for further characterization.  
SDAHER3-A1 and SDAHER3-D5 showed great binding affinity to ErbB3 in vitro and 
selectively binds to ErbB3-positive cells 
SDAHER3-A1 and SDAHER3-D5 were expressed and purified for characterization. 
For labeling purpose, SDAHER3-A1-Cys and SDAHER3-D5-Cys were constructed, 
expressed and purified. ProteOn XPR36 was used to determine the binding affinity of 
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SDAHER3s to ErbB3. Both SDAHER3-A1 and SDAHER3-D5 did not bind to immobilized 
EGFR-ECD-Fc (data not shown). The KD of SDAHER3-A1 and SDAHER3-D5 were 1.50 ± 
0.38 nM and 4.14 ± 0.20 nM, respectively (Figure 2.3). The binding mode of the two 
SDAHER3s may be slightly different. Although the on-rate constants were similar, the off-
rate constant of SDAHER3-D5 was greater than that of SDAHER3-A1. Overall, both 
SDAHER3s have nanomolar binding affinity to ErbB3 in vitro. 
Binding to the purified receptors in vitro does not guarantee the binding to the 
native receptors on the surface of cells. To confirm the binding of SDAHER3s to ErbB3 
receptors on the surface of cancer cells, confocal cell binding assays were performed 
with Alexa-Fluor 555-labeled SDAs. Four cell lines were used in this experiment. ASPC-
1 and MDA-MB-453 cells were with high expression of ErbB3 while MDA-MB-231 and 
SKOV3 cells were with very low expression of ErbB3. To exclude the non-specific 
binding outside the randomized loops, wild-type FN3 proteins were expressed, purified 
and labeled. As illustrated in Figure 2.5, 500 nM and 1 μM labeled SDAHER3-A1 and 
SDAHER3-D5 all showed binding to the ErbB3-positive ASPC1 cells. However, none of 
them bound to the ErbB3-negative MDA-MB-231 cells (Figure 2.6). Figure 2.7 shows 
that 1 μM labeled wild-type FN3 proteins bound to neither ErbB3-positive (MDA-MB-
453) or ErbB3-negative (SKOV3) cells. It suggested the backbone structure of FN3 
proteins do not have non-specific binding to the selected cell lines. The selected 
SDAHER3s selectively bind to ErbB3-positive cell line and may be very useful for further 
development and application. 
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Discussion 
Most of the known agents that bind to ErbB3 in pre-clinical and clinical 
development are based on mAbs37. However, the process of producing mAbs and the 
properties of antibodies may limit the potentials in modification and further development. 
Therefore, smaller proteins with high expression and minimum immunogenicity may be 
great tools for research investigation. Göstring and his colleagues presented an 
affibody-based agent that bind to ErbB3 through phage display56,57. Affibody is a 
structure based on Z domain of protein A, with three α-helices and a size of approximate 
6 kDa. Generally, its binding ability comes from the randomization of 13 amino acids 
located on the two helices58. The size of the affibody and the limited number of 
randomization region may be a limitation for its application. In contrast, FN3-based 
protein has larger size and three loops that can be randomized. Moreover, there is an 
FN3-based scaffold based drug and it has already been in clinical trials for treatment59. 
In the present study, the two mRNA-display selections based on FN3 library 
successfully identified some proteins with distinct sequences. The SDAHER3s identified 
by the general elution approach may bind to any position of the extracellular domain of 
ErbB3; while SDAHER3s selected from the ligand elution approach may be able to 
compete with NRG1. The design and the purpose of the second approach is to find 
SDAs that have similar binding affinity to NRG1 and share the same/partial binding site 
of NRG1. SDAHER3-D5 was screened via the later approach. The binding affinity of 
SDAHER3-D5 is relatively close to the binding affinity of NRG1 to ErbB3 (5.4 nM60), which 
is quite consistent with the experiment design. On the contrary, the general elution may 
screen SDAs that have much higher binding affinity to ErbB3 than NRG1. As a result, 
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SDAHER3-A1 from general elution approach has ~ 4 folds higher binding affinity to 
ErbB3. Interestingly, SDAHER3-A1 has a higher k-on rate and lower k-off rate than those 
of SDAHER3-D5 in vitro. Regarding the cellular binding, the wt-FN3 protein was used as 
a control to rule out the backbone structure that contributes to the ErbB3 binding. In 
confocal microscopy study, both SDAHER3-A1 and SDAHER3-D5 selectively bound to the 
receptor on the surface of ErbB3-positive cell line in a concentration dependent manner. 
Overall, the experiment results suggested the selections were successful and we 
identified two SDAHER3s, SDAHER3-A1 and SDAHER3-D5, that selectively bind to ErbB3 
receptor with high affinity. 
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Figure 2.1 Selection strategies by general elution and ligand-specific competitive 
elution. 
The general elution approach is designed to amplify and select SDAs that bind to the 
extracellular domain of ErbB3; the ligand-specific competitive elution selected SDAs 
that bind to ErbB3 and may be competed off the ligand by NRG1, which suggested the 
SDAs might share binding site with NRG1. 
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Figure 2.2 The Changes in Recovery Percentages Show Enrichment in two 
Selections 
The change in recovery percentage from general (left) and ligand-specific (right) elution 
approaches through rounds of selections. The recovery rates reached 33.2% at round 8 
in general elution approach and 19.8% at round 9 in ligand-specific elution approach, 
respectively. 
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Figure 2.3 The binding affinity of selected SDAHER3s against ErbB3 ECD-Fc in vitro 
by ProteOn XPR36 
  
(a) Binding affinity for SDAHER3-A1 against ErbB3 was 1.50 ± 0.38 nM 
 
(b) Binding affinity for SDAHER3-D5 against ErbB3 was 4.14 ± 0.20 nM 
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Figure 2.4 The binding of SDAHER3-A1 and SDAHER3-D5 to ErbB3-positive ASPC1 
cells were confirmed by confocal microscopy 
The SDAHER3-A1 and SDAHER3-D5 were labeled with Alexa-Fluor 555 through the 
reaction between cysteine residue and maleimide, and showed concentration 
dependent binding to the ASPC1, a pancreatic cancer cell line with ErbB3 
overexpressed. 
 
 
  
27 
 
Figure 2.5 Confocal microscopy confirmed that SDAHER3-A1 and SDAHER3-D5 did 
not bind to ErbB3-negative MDA-MB-231 cells 
The SDAHER3-A1 and SDAHER3-D5 were labeled with Alexa-Fluor 555 through the 
reaction between cysteine residue and maleimide, and showed no binding to MDA-MB-
231, a breast cancer cell line, with no/minimum ErbB3 expression. 
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Figure 2.6 The WT-FN3 showed no binding to ErbB3-positive or ErbB3-negative 
cell lines by confocal microscopy 
The WT-FN3 protein was labeled with Alexa-Fluor 555. It showed no binding to MDA-
MB-453 (ErbB3+, breast cancer) or SKOV3 (ErbB3-, ovarian cancer), which exclude the 
possibility that the binding comes from the backbone structure of FN3. 
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CHAPTER 3  
Generation and characterization of a biparatopic ErbB3-targeting SDAHER3 
 
Introduction 
Cancer is a complex disease, which usually involves multi-factors during the 
development and progression. Bispecific antibodies draw attention in the field of 
immunotherapy and oncology. The major interests in bispecific antibodies are to 
combine two fragments from two different monoclonal antibodies that bind to different 
antigens. Although it is indeed interesting in engineering a bispecific SDA, in the present 
study, we focused on developing biparatopic agent that targeting solely against ErbB3. 
There were a few studies indicated the advantages of biparatopic antibodies/proteins 
targeting other members of ErbB family or other receptors61–64. Roovers and his 
colleagues combined two anti-EGFR nanobodies that improve the efficacy and potently 
inhibited the EGF-depend cell proliferation64. Li from MedImmune demonstrated an  
biparatopic ErbB2-targeting antibody-drug conjugate having therapeutic effect in T-DM1 
eligible, resistant and ineligible patients during pre-clinical trials61.  
As introduced in the first chapter, the currently ErbB3 antibodies under 
development has three major mechanism of actions, targeting the NRG1 binding, 
disrupting the dimerization between other ErbB receptors, or inducing the degradation 
of ErbB337. In our study, the selected two SDAs from two selections have distinct 
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sequences, as well as slightly different binding affinities. Therefore, it was suspected 
that the two SDAs, SDAHER3-A1 and SDAHER3-D5, bind to the extracellular domain of 
ErbB3 at different sites. Moreover, the solubility and stability of SDAHER3-D5 was not as 
good as that of SDAHER3-A1. In order to improve the biophysical properties of the 
selected SDAs, and take the advantage of the biparatopic agent, SDAHER3-A1 and 
SDAHER3-D5 were linked together by a flexible linker. The new biparatopic SDAHER3 was 
constructed, expressed and purified. The biochemical characteristics and cellular effects 
of the new agent were also tested.  
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Materials and Methods 
Construction, expression and purification of SDAHER3-D5A1 and SDAHER3-D5A1-
Cys 
The coding gene of SDAHER3-D5A1 was optimized first. The plasmid for SDAHER3-
D5A1-Cys was synthesized by Genescript. The plasmid was transformed to E.coli DH5α 
(New England BioLabs) and amplified. Part of the extracted plasmid was transformed to 
E.coli BL21 (DE3) competent cells (New England BioLabs) for protein expression. The 
other part of the plasmid was digested with Nco I & Sal I (New England BioLabs) and 
ligated to digested pET28b plasmid (by Nco I & Xho I, New England BioLabs). The 
ligated plasmid was confirmed by DNA sequencing (Eton BioScience) and transformed 
to E.coli BL21 (DE3) competent cells (New England BioLabs) as well. Cells were grown 
in LB media with kanamycin at 37 °C until OD ~0.6 (600 nm) and then induced with 0.3 
mM IPTG at 20 °C for 16 h. The purification process was performed as above.  
Affinity determination and specificity by Bio-Layer Interferometry (BLI) analysis  
The binding affinity and specificity of SDAHER3-D5A1 was determined on an Octet 
RED384 instrument (Pall Fortbio, UNC Macromolecular Interactions Facility). All 
measurements were ran at 30 °C with black 96-well microplates (Greiner Bio-One). 
Anti-human IgG Fc Capture (AHC) biosensors (Pall Fortbio) were used for 
measurements. Human EGFR ECD-Fc, ErbB2 ECD-Fc, ErbB3 ECD-Fc and ErbB4 
ECD-Fc (R&D Systems) were dissolved in the running buffer (1 x PBS, 0.002% Tween 
20, pH 7.4). Receptors were immobilized to the biosensors with a concentration of 
5ug/well. The concentration of the SDAs varied according to different types of proteins 
in different experiments. The data were obtained by data acquisition software from 
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forteBio. The acquired data was further processed and analyzed by data analysis 
software from forteBio. All the binding curves were performed by a 2:1 hetero- binding 
model.  
Labeling SDAHER3-D5A1 for cellular binding 
For protein labeling, SDAHER3-D5A1-Cys was used to react with Alexa-Fluor 555 
C2 maleimide (Life technologies) following the steps as described previously. SDAHER3-
D5A1 was reacted with Cyanine5.5 NHS ester (Lumiprobe), with the same steps as 
described previously for SDAs reacting with Alexa-Fluor 555 carboxylic acid. All the 
labeled proteins were further purified with NAP-5 column (GE healthcare) to remove 
excess fluorescent dyes. 
Cell culture 
ErbB3-positive MDA-MB-453, MCF7, BT474 and ErbB3-negative MDA-MB-231, 
SKOV3, PANC1 were obtained from UNC Tissue Culture Facility. Each cell line was 
cultured by serial passage with proper media in 5% CO2 incubator, at 37 °C. 
Confocal microscopy and competition study 
The binding test of SDAHER3-D5A1 was performed similar to what has been 
described above, except the incubation was 30 min at room temperature. For 
competition experiments, the unlabeled SDAHER3-A1, SDAHER3-D5 and SDAHER3-D5A1 
were pre-mixed with Alexa-Fluor 555-labled SDAHER3-D5A1-Cys in a ratio of 10:1 
(2µM:200nM) before incubating with cells. The sample preparation was the same as 
previously described. All samples were examined with Zeiss LSM 700 confocal 
microscopy at UNC Microscopy Services Laboratory (MSL).  
Flow cytometry and cell-binding study 
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Cellar binding affinity of SDAHER3-D5A1 was determined by flow cytometry. 
Approximately 3 x 104 cells were collected. The cells were washed with 1 x PBS first. 
One set of cells were pre-blocked with 5 µM unlabeled SDAHER3-D5A1 first for 30 
minutes at 37 °C to get the non-specific binding signals. Then all cells were incubated 
with 0, 62.5, 125, 250, 500, 1000 nM SDAHER3-D5A1-Cy5.5 samples on ice for 1 h, 
followed by 1 x PBS washing twice. The cells were fixed with 2% paraformaldehyde 
(PFA) for 15 min and washed by 1 x PBS once. The samples were analyzed by a flow 
cytometry (Cyan ADP analyzer, UNC flow cytometry core). Summit 4.4 (Beckman 
Coulter) and GraphPad Prism 6 was used for data analysis. 
Cell proliferation assay 
CellTiter 96 AQueous one solution cell proliferation assay (Promega) was used for 
cell proliferation MTS assay. Approximately 5 x 104 cells were seeded in each (96 well 
plats) and grew overnight at 37 °C. The cells were starved with appropriate media 
containing 1% FBS for 24 hours at 37 °C. Different concentrations of SDAHER3-D5A1 
were incubated with cells for 48 hours at 37 °C. The MTS assay followed the manual 
provided by the manufacture and the absorbance at 485 nm was recorded using a HTS 
7000 bioassay plate reader (PERKin Elmer).  GraphPad Prism 6 was used for data 
analysis. 
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Result 
Construction, expression and purification of SDAHER3-D5A1 and SDAHER3-D5A1-
Cys  
The genetic code for SDAHER3-D5A1 was optimized for expression. The 
construction, expression and purification of SDAHER3-D5A1 and SDAHER3-D5A1-Cys 
were successful. The biparatopic SDAHER3-D5A1 has increased level of expression, as 
well as with improved stability and solubility. The Figure 3.1 showed the purified 
products of SDAHER3-D5A1 and SDAHER3-D5A1-Cys on SDS-PAGE gel. The size of the 
two products were consistent with design and the purities were satisfying. The 
generated SDAHER3-D5A1-Cys provided modification sites for conjugation and 
applications.  
SDAHER3-D5A1 binds to ErbB3 with picomolar affinity and specificity in vitro, and 
it selectively binds to ErbB3-positive cells 
The biparatopic molecule usually has greater binding affinity than its 
components. It is consistent in our study. The generated SDAHER3-D5A1 molecule has 
picomolar affinity (80.3 ± 20.3 pM) to ErbB3 whose binding affinity is about 10 x tighter 
than that SDAHER3-A1 and 30 x than that of SDAHER3-D5. The dissociation rate of 
SDAHER3-D5A1 was very slow, as shown in Figure 3.2. Human EGFR ECD-Fc, ErbB2 
ECD-Fc, ErbB3 ECD-Fc and ErbB4 ECD-Fc were used for specificity test (Figure 3.3). 
SDAHER3-D5A1 did not bind to EGFR and ErbB2, however, it showed binding to ErbB4 
besides ErbB3. Considering the fact that NRGs are the ligands for ErbB3 and ErbB4, it 
is reasonable that our SDA also has binding affinity to ErbB4. To confirm the binding 
and possible mechanism of SDAHER3-D5A1 against ErbB4, the KD was measured as 
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16.5±6.8 nM (Figure 3.4), which is almost 200 fold weaker than its binding to ErbB3. 
The binding of SDAHER3-A1, SDAHER3-D5 and SDAHER3-D5A1 against ErbB4 with the 
same concentration was also tested as shown in Figure 3.5. The result supported the 
hypothesis that the binding of SDAHER3-D5A1 against ErbB4 may related to the NRG1 
binding sites since only SDAHER3-D5 that may compete with NRG1. However, the 
binding affinity of the SDAHER3-D5A1 against ErbB4 is much higher than SDAHER3-D5. 
Overall, SDAHER3-D5A1 selectively bind to the extracellular domain of ErbB3 with 
picomolar binding affinity in vitro. 
The binding of SDAHER3-D5A1 to ErbB3 receptors on cell surface was confirmed 
by confocal microscopy as shown in Figure 3.6. MDA-MB-453 is a breast cancer cell 
line with ErbB3 overexpressed and SKOV3 is an ovarian cancer cell line with 
no/minimum ErbB3 expression. The labeled SDAHER3-D5A1 showed cellular binding 
when incubated with MDA-MB-453 cells and did not bind to SKOV3 cells. It suggested 
that SDAHER3-D5A1 selectively bind to ErbB3 overexpressed cancer cells. 
Competition assay supported that SDAHER3-D5A1 is a biparatopic molecule and 
binds to ErbB3 
The availability of SDAHER3-D5A1 made it possible to check whether SDAHER3-A1 
and SDAHER3-D5 bind to different sites on the extracellular domain of ErbB3. A 
competition test was performed with confocal microscopy. If the binding of SDAHER3-A1 
and SDAHER3-D5 compete with each other, then either SDAHER3-A1 or SDAHER3-D5 is 
able to block the binding of labeled SDAHER3-D5A1. As shown in Figure 3.7, with 30 min 
incubation at room temperature, the confocal data clearly demonstrated the binding of 
200 nM labeled SDAHER3-D5A1 to the ErbB3-positive MCF7 cells. A 10 x concentrated 
36 
 
unlabeled SDAHER3-D5A1 was used as a positive control. After being mixed together 
with labeled SDAHER3-D5A1, and the binding of labeled SDAHER3-D5A1 was totally 
blocked. However, when mixed with 10 x concentrated SDAHER3-A1 or SDAHER3-D5, the 
labeled SDAHER3-D5A1 still showed cellular binding to MCF7 cells. Only when mixing 
with 10 x concentrated SDAHER3-A1 and SDAHER3-D5 together, the binding of labeled 
SDAHER3-D5A1 was then attenuated. The results implied that SDAHER3-A1 and SDAHER3-
D5 did not compete with each other when binding to ErbB3, and the new SDAHER3-
D5A1 molecule is indeed a biparatopic molecule. 
Cellular binding affinity of SDAHER3-D5A1 to ErbB3-positive cell line 
The cellular binding affinity of SDAHER3-D5A1 was determined by flow cytometry. 
Cells were pre-blocked with 5 µM SDAHER3-D5A1 to induce the internalization of the 
surface ErbB3 receptors. Therefore, the results from the pre-blocked samples can be 
considered as the non-specific binding. After the subtraction the background and 
normalization, the data was fitted by the one-site specific binding in GraphPad Prism. 
The KD of SDAHER3-D5A1 to ErbB3-positive MCF7 cells is 35.61 ± 17.07 nM. For ErbB3-
negative PANC1 cells, the fitting curve for SDAHER3-D5A1 did not converge, and the 
binding signal before normalization was much smaller than that with MCF7 cells. The 
result suggested that SDAHER3-D5A1 selectively binds to ErbB3-positive cells with ~30 
nM cellular binding affinity. 
SDAHER3-D5A1 inhibited the NRG1 induced proliferation 
MTS assay was used to determine whether SDAHER3-D5A1 has any effect on cell 
proliferation. Sheng and his colleagues proposed the important role of NRG/ErbB3 
autocrine loop65. The autocrine ligand-receptor stimulates growth stimulation and 
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tumorigenesis in cancers45. Two ErbB3-positive breast cancer cells, MCF7 and BT474, 
as well as ErbB3-negative MDA-MB-231 cells, were used to perform the proliferation 
assay. The SDAHER3-D5A1 did not show any inhibition effect on any of the cell lines 
alone (as shown in Figure 3.9 for BT474 cell line). However, after the stimulation by 10 
nM NRG1, SDAHER3-D5A1 inhibited the ligand-induced proliferation of MCF7 and 
BT474. Different concentrations of SDAHER3-D5A1 were applied and the results showed 
a dose-dependent inhibition effect. To calculate the growth inhibition, the readings from 
stimulated cells were subtracted by the readings from unstimulated ones according to 
different treatments. The final readings were normalized and fitted by (logged) 
concentration vs. normalized response curves. The EC50 of the inhibition to the ligand-
induced proliferation are 52.72 ± 12.44 nM and 178.8 ± 64.7 nM with SDAHER3-D5A1 for 
BT474 and MCF7 cells, respectively, as shown in Figure 3.10. The ErbB3-negative 
PANC1 cells did not stimulated by NRG1, thus the SDAHER3-D5A1 showed no inhibition 
effect. In all, SDAHER3-D5A1 did not inhibit the normal cancer cell growth; however, it 
inhibits the NRG1-induced cell proliferation in cancers that are ErbB3-driven or through 
ErbB2-ErbB3 dimerization. SDAHER3-D5A1 may be a good candidate for cancer 
treatment or in combination with other therapeutic agents.  
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Discussion 
In the present study, we constructed a biparatopic molecule SDAHER3-D5A1 that 
targets the extracellular domain of ErbB3 from SDAHER3-A1 and SDAHER3-D5. SDAHER3-
D5A1 has an improved level of expression, solubility and stability. Similar to the 
biparatopic anti-VEGFR nanobody reported by Fleetwood and his colleagues62, the 
generated SDAHER3-D5A1 has picomolar binding affinity to ErbB3 with specificity in vitro, 
which makes SDAHER3-D5A1 a good candidate for further development. Cellular binding 
of SDAHER3-D5A1 was confirmed by confocal microscopy and a KD was determined by 
flow cytometry. SDAHER3-D5A1 selectively binds to ErbB3-positive cell lines. However, 
the cellular binding affinity is much weaker than the binding affinity determined by Octet 
Red. It may due to the limitation of the fluorescence molecules or the flow cytometry 
machine. The enriched ErbB3 concentration on the surface of the anti-Fc sensors by 
immobilization may artificially increase the binding affinity. It is also because of the 
conjugation of the dye that effect the cellular binding affinity. The result from the 
competition assay by confocal microscopy supported the assumption that SDAHER3-A1 
and SDAHER3-D5 bind to different site of ErbB3 and does not compete with each other, 
and the constructed SDAHER3-D5A1 is indeed a biparatopic molecule. Once we 
confirmed the binding of SDAHER3-D5A1, the next step was to evaluate the cellular effect 
of SDAHER3-D5A1. Lee-Hoeflich and her colleagues explored the role of ErbB3 in 
ErbB2-amplified breast cancer. They discovered that the knockdown of ErbB3 inhibited 
the growth BT474 tumor and induced tumor regression66.  In low ErbB2-expressing 
cancer cells such as MCF7, ErbB3 is also a key sensor in regulating ErbB-mediated 
signaling pathways67.  Clinical studies with ErbB3-targeting antibody MM-121 has 
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already proved its usage in breast cancer patients with low-expression of ErbB268. In 
the present study, PANC1 was used as a negative control for proliferation assay. No 
stimulation from PANC1 was observed. Thus, there is no inhibition effect from the 
addition of SDAHER3-D5A1. BT474 is a cell line with overexpression of ErbB2 and 
ErbB3, while MCF7 has low expression of ErbB2. Both of the cell lines were stimulated 
by 10 nM NRG1. The result suggested that SDAHER3-D5A1 has better (about three 
folds) inhibition effect to the ligand-induced proliferation in BT474 cells than MCF7 cells.  
It may imply that SDAHER3-D5A1 is able to disrupt the dimerization of ErbB2-ErbB3, 
which contributes to the improved inhibition effect in BT474 cells. Lazrek and his 
colleagues reported a combination of anti-ErbB3 domain I and III antibodies effectively 
inhibited tumor growth by disrupting the dimerization and Akt induced downstream 
signaling pathways69, which is consistent with our result. Therefore, it is possible that 
our biparatopic SDAHER3-D5A1 has similar mechanisms in inhibition ligand-induced 
proliferation. Overall, SDAHER3-D5A1 has potentials to be a therapeutic agent targeting 
ErbB3-overexpressed cancer cells. 
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Figure 3.1 Purification of SDAHER3-D5A1 and SDAHER3-D5A1-Cys 
SDS-PAGE (12%) of the purified SDAHER3-D5A1 and SDAHER3-D5A1-Cys by Ni-NTA 
resin. The SDAHER3-D5A1 was a monomer with a size ~30 kDa while SDAHER3-D5A1-
Cys was a mixture of monomer and dimer (~60 kDa). The cartoon illustrated the 
schematic and design of SDAHER3-D5A1.  
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Figure 3.2 The binding affinity of SDAHER3-D5A1 to ErbB3 ECD-Fc 
Four different concentration (31.25 nM, 62.5 nM, 125 nM, 250 nM) of SDAHER3-D5A1 
were used in the binding experiment. Similar to SDAHER3-A1 and SDAHER3-D5, SDAHER3-
D5A1 has good on-rate. SDAHER3-D5A1 has slower dissociation rate if compared to the 
parent SDAs. The calculated KD for SDAHER3-D5A1 to ErbB3 is 80.3 ± 20.3 pM, which 
increases ~ 10 fold binding affinity to that of SDAHER3-A1.   
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Figure 3.3 Selectivity of SDAHER3-D5A1 to ErbB receptor family 
Human EGFR ECD-Fc, ErbB2 ECD-Fc, ErbB3 ECD-Fc and ErbB4 ECD-Fc were 
immobilized to anti-Fc sensors. 500 nM of SDAHER3-D5A1 was used to test whether 
SDAHER3-D5A1 binds to the ErbB receptors. SDAHER3-D5A1 showed no/minimum 
binding to the extracellular domain of EGFR and ErbB2. It showed binding to both 
ErbB3 and ErbB4 while it has much stronger binding affinity to ErbB3. 
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Figure 3.4 Binding affinity of SDAHER3-D5A1 against ErbB4 
The binding affinity of SDAHER3-D5A1 against ErbB4 was determined as 16.5±6.8 nM. 
The association SDAHER3-D5A1 to ErbB4 were much slower than that to ErbB3 and the 
dissociation of SDAHER3-D5A1 to ErbB4 were much faster. 
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Figure 3.5 The binding curve of SDAHER3-A1, SDAHER3-D5 and SDAHER3-D5A1 to the 
extracellular domain of ErbB4 
To explore the potential binding mode of SDAHER3-D5A1 against ErbB4, 500 nM of 
SDAHER3-A1, SDAHER3-D5 and SDAHER3-D5A1 were used to get the binding curves to 
ErbB4. Interestingly, SDAHER3-A1 does not bind to ErbB4 and SDAHER3-D5 only has 
small response during the association. SDAHER3-D5A1 itself has much stronger binding 
to ErbB4 than its parent subunits. 
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Figure 3.6 SDAHER3-D5A1 selectively binds to ErbB3-positive cell line 
The SDAHER3-D5A1-Alexa-Fluor 555 showed binding to MDA-MB-453, a breast cancer 
cell line, with ErbB3 overexpressed; but the same molecule did not show binding to 
SKOV3, an ovarian cancer cell line with no/minimum ErbB3 expressed.  
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Figure 3.7 Competition experiment with confocal microscopy supported the 
hypothesis that SDAHER3-D5A1 is biparatopic molecule 
The competition assay confirmed that SDAHER3-A1 and SDAHER3-D5 bind to different 
locations on the extracellular domain of ErbB3, thus, SDAHER3-D5A1 is a biparatopic 
molecule. Neither 10 x excess of unlabeled SDAHER3-A1 nor SDAHER3-D5 blocked the 
binding of SDAHER3-D5A1. Only the presence of both SDAHER3-A1 and SDAHER3-D5, or 
SDAHER3-D5A1 itself blocked the binding of the Alexa-Fluor 555 labeled SDAHER3-D5A1.  
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Figure 3.8 Flow Cytometry confirmed SDAHER3-D5A1 selectively bind to ErbB3-
positive cell line with good binding affinity. 
The binding affinity of Cy5.5 labeled SDAHER3-D5A1 to ErbB3-positive MCF7 is 35.61 ± 
17.07 nM. The same molecule did not show concentrated dependent binding to PANC1 
cells and the values of MFI were very small (data not shown).  
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Figure 3.9 SDAHER3-D5A1 does not stimulate or inhibit the normal cell growth 
while it inhibits the NRG1 stimulated cell proliferation 
Different concentrations of SDAHER3-D5A1 were applied to the BT474 cells and 
incubated for 48 hours. The protein did not stimulate or inhibit the cell growth of BT474 
cells without the stimulation of NRG1. However, with the stimulation from NRG1, 
SDAHER3-D5A1 showed a dose-dependent inhibition to the NGR1 stimulated cell 
proliferation. 
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Figure 3.10 SDAHER3-D5A1 showed growth inhibition to NRG1 stimulated 
proliferation for ErbB3-positive cell lines selectively 
Different concentration of SDAHER3-D5A1 were used to test the proliferation stimulated 
by 10 nM NRG1 of three different cancer cell lines, BT474 and MCF7 as ErbB3-positive 
cell lines, and PANC1 as ErbB3-negative cell line. The EC50 of the inhibition to the 
ligand-induced proliferation are 52.72 ± 12.44 nM and 178.8 ± 64.7 nM for BT474 and 
MCF7 cells, respectively. PANC1 did not stimulated by NRG1 and SDAHER3-D5A1 
showed no inhibition effect. 
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CHAPTER 4 
Biparatopic ErbB3-targeting SDAHER3 as a theranostic agent 
 
Introduction 
Antibody-based drugs become a major new class of drugs in the recent years70. 
The mAbs with high affinity against important receptor targets have been proved very 
efficient and selective in clinical trials and treatments. Antibodies can be used as 
therapeutic agents, drug-delivery agents, or conjugated with imaging agents. It is well 
known that antibodies can be protein-based therapeutic agents for treatment. ADC with 
toxins71 and targeted system for cancer therapy72 attracts attentions in both academia 
and industry. Antibodies that targeting cell surface biomarkers can be used for 
molecular imaging of cancers as well73. For example, anti-ErbB2 antibody trastuzumab 
is among the first generation of antibody drugs. Originally, trastuzumab was used alone 
to treat late stage ErbB2-positive breast cancer74. A combination of trastuzumab with 
chemotherapy improved the survival and response rates75. Ado-trastuzumab emtansine 
is an antibody-drug conjugate of trastuzumab and a cytotoxic drug emtansine (DM1). It 
is used for treating patients with ErbB2-positive metastatic breast cancer and improves 
the progression-free and overall survival rate76. Other treatments includes combining 
trastuzumab with Lapatinib, or with pertuzumab and docetaxel, to improve the response 
and survival rates29,77. Besides the therapeutic effect from the monoclonal antibody and 
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ADC, trastuzumab was labeled with imaging agents such as IRDye800 and used for 
imaging purpose in mice xenograft models78.  
In most of the pre-clinical and clinical trials, the ErbB3 targeting antibodies were 
used as a combination of other agents for treatment37. ErbB3 is also a good candidate 
for targeted drug delivery79. Terwisscha van Scheltinga and Rosestedt presented their 
studies in utilizing ErbB3 targeting antibody and affibody in PET imaging, 
respectively80,81. In the present study, we performed some preliminary studies by 
utilizing the SDAHER3-D5A1/ SDAHER3-D5A1-Cys and different agents, including 
internalization and the delivery of gold nanoparticles, synergistic effect of applying 
SDAHER3-D5A1 and Lapatinib together, and SDAHER3-D5A1 with imaging agent in living 
mice. 
  
52 
 
Materials and Methods 
Cell culture 
ErbB3-positive ASPC1, MCF7, BT474 and ErbB3-negative MDA-MB-231, 
SKOV3, PANC1 were obtained from UNC Tissue Culture Facility. Each cell line was 
cultured by serial passage with proper media in 5% CO2 incubator, at 37 °C. 
Confocal microscopy and internalization assay 
The SDAHER3-D5A1-Cys was conjugated with Alexa-Fluor 555 C2 maleimide as 
previously described. The internalization test of SDAHER3-D5A1 was performed similar to 
what has been described above, except the incubation was 2 hours at 37 °C. The 
sample preparation was the same as previously described. All samples were examined 
with Zeiss LSM 700 confocal microscopy at UNC Microscopy Services Laboratory 
(MSL).  
AuNPs-mediated hyperthermia treatment with cancer cells 
The conjugation of SDAHER3-D5A1-Cys with AuNPs followed the steps as 
described in the previous work53. The quantification was performed with Bradford Assay 
Reagent (Thermo Scientific). ErbB3-positive MCF7 and MDA-MB-231 cells were 
seeded on the glass coverslides. After the treatment53, the cells were stained by 
LIVE/DEAD® Viability/Cytotoxicity Kit, for mammalian cells (Life Technologies). After 
washing by 1 x PBS 3 times and fixed, the samples were examined by Zeiss LSM 700 
at UNC Microscopy Services Laboratory (MSL).  
Cell proliferation assay 
CellTiter 96 AQueous one solution cell proliferation assay (Promega) was used for 
cell proliferation MTS assay. The procedure was the same as described in the previous 
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chapter. The Lapatinib (Sigma) was dissolved in DMSO. Different concentration and 
combination of SDAHER3-D5A1 and Lapatinib was used according to the IC50 of 
Lapatinib (BT474 ~ 25 nM, MCF7 ~ 6 µM, MDA-MB-231 ~ 6 µM)82–84 and incubated for 
48 hours at 37°C. The MTS assay followed the manual provided by the manufacture 
and the absorbance at 485 nm was recorded using a HTS 7000 bioassay plate reader 
(PERKin Elmer). GraphPad Prism 6 was used for data analysis. 
Western blot analysis 
 Cells were seeded to 6 well plates and grew overnight. Cells were starved for 24 
hours with media containing 1% FBS. Cells were stimulated with 10 nM NRG1 and 
different combinations of agents (200 nM SDAHER3-D5A1, 2 µM Lapatinib) for 10 
minutes. Cell lysates were quantified by DC Protein Assay (Bio-Rad) and separated by 
12% SDS-PAGE gel. After transferred to the membrane, the corresponding strips were 
cut and incubated with antibodies, including phosphor-HER3/ErbB3 (21D3) Rabbit mAb 
(Cell Signaling), HER3/ErbB3 (1B2E) Rabbit mAb (Cell Signaling), phosphor-Akt 
(Ser473) XP Rabbit mAb (Cell Signaling), Akt(pan) (C67E7) Rabbit mAb (Cell 
Signaling), Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) Rabbit mAb (Cell 
Signaling), p44/42 MAPK (ERK1/2) (137F5) Rabbit mAb (Cell Signaling), respectively, 
in a ratio of 1:2500 for 16 hours at 4 °C. ECL anti-rabbit IgG (GE healthcare) was used 
as secondary antibody. 
 Synthesis of IRDye 800-SDAHER3-D5A1 and imaging study 
Synthesis of SDAHER3-D5A1-Cys and IRDye800CW Maleimide (LI-COR 
biosciences) followed the same steps as described in the previous section for thio-
reactive dye with SDAHER3-D5A1. The efficiency of the conjugation was determined by 
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NanoDrop 1000 (Thermo Fisher Scientific). The excessive dye was removed by NAP-5 
column (GE healthcare). 
A total of fifteen 4-6 weeks BALB/c nude mice (obtained from UNC animal study 
facility) were used for the present study. For each mouse, 5 million cells were injected to 
the shoulder. Ten mice were injected with ErbB3-positive ASPC1 cells and five mice 
were injected with ErbB3-negative PANC1 cells. After the tumor grew to a size of 200-
500 cm3, the mice were injected with labeled agents for imaging purpose. Mice 
anesthesia was conducted with 2-5% isoflurane in oxygen with a flow rate of 2L/min. 
Each mice was injected with 100 µL labeled agents. The time points for imaging were 1 
hour, 4 hours, 12 hours and 24 hours. IVIS Kinetic (Caliper Life Sciences) was used to 
acquire quantitative fluorescence signals. The emission filter was ND3, and the excitation 
filter was 745. The result was analyzed by Living image software and the data was 
processed with GraphPad Prism. 
  
 
  
55 
 
Result 
SDAHER3-D5A1 got internalized and selectively targeted ErbB3-positive cells in 
hyperthermia treatment. 
In the previous section, we confirmed the binding of SDAHER3-D5A1 to the 
receptor ErbB3 on the surface of cancer cells. In this experiment, as shown in Figure 
4.1, at 37 °C for 2 hours, the labeled SDAHER3-D5A1 entered the cells.  To validate the 
targeting effect of SDAHER3-D5A1, SDAHER3-D5A1-Cys was conjugated with gold 
nanoparticles and used for hyperthermia treatment. The result in Figure 4.2 illustrated 
that the SDAHER3-D5A1-AuNP was selectively delivered into the ErbB3-positive MCF7 
cells. With laser irradiation, the cancer cells were killed by the heating effect from the 
internalized AuNPs. However, using SDAHER3-D5A1-AuNP did not have toxicity to the 
cells, and SDAHER3-D5A1-AuNP did not target ErbB3-negative cells. Moreover, the 
AuNP without targeting ligands did not internalized into the normal cells. Therefore, 
SDAHER3-D5A1-AuNP showed improved targeting efficiency of biomaterials and 
demonstrated biomarker-dependent killing effect to cancer cells. 
A combination of SDAHER3-D5A1 and Lapatinib showed improved inhibition 
efficiency in proliferation assay with ErbB2 and ErbB3 overexpressed cells 
In the previous chapter, SDAHER3-D5A1 demonstrated its inhibition effect on 
ligand-induced proliferation. Additional proliferation assays were performed to explore 
its synergistic effect with Lapatinib, an EGFR/ErbB2 TKI, on ErbB3-overexpressed cells. 
MCF7 is a cell line with overexpressed ErbB3 but low expression of ErbB2. BT474 is a 
cell line with both ErbB2 and ErbB3 overexpressed. MDA-MB-231 is a triple negative 
breast cancer cell line with low/minimum expression of ErbB3. Although both MCF7 and 
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MDA-MB-231 have some EGFR expressed85 on the cell surface, they are not very 
sensitive to Lapatinib83,84; In contrast, Lapatinib efficiently inhibits the proliferation of 
BT474. The results were described in Figure 4.3 for MCF7 cell line, Figure 4.4 for 
BT474 cell line, and Figure 4.5 for MDA-MB-231 cells. Overall, when adding Lapatinib 
with a concentration near the IC50 value, the drug itself did not effectively inhibit the 
proliferation, but a combination of SDAHER3-D5A1 and Lapatinib further inhibit the cell 
proliferation in ErbB2 and ErbB3-positive cell line (BT474) as an addition effect, which is 
consistent with the result from the previous chapter. However, it did not show effect with 
statistical significance with MCF7 cells. Therefore, it may be useful in developing 
combination therapy with Lapatinib in treating ErbB2 and ErbB3-positive cancers. 
SDAHER3-D5A1 inhibited the ligand-induced activation of the downstream 
pathways 
 PI3K/Akt and MAPK/ERK pathways are important downstream pathways of 
ErbB3 and the whole ErbB family. To check the activation and inhibition of the 
downstream pathways, the phosphorylation of ErbB3, Akt and ERK1/2 was checked by 
western blot analysis, as shown in Figure 4.6. The result suggested that the addition of 
SDAHER3-D5A1 alone did not influence the downstream pathways. After adding 10 nM 
NRG1, the cells were stimulated and the elevated levels of phosphorylation were 
observed for ErbB3, Akt and ERK. Since Lapatinib is kinase inhibitors and it could not 
inhibit ErbB3, the addition of the drug only showed minor effect on Akt and ERK, 
possibly by targeting EGFR. Applying 200 nM SDAHER3-D5A1 partially inhibited the 
phosphorylation of all three targets. A combination treatment of 200 nM SDAHER3-D5A1 
and 2 μM Lapatinib further inhibit the ligand induced phosphorylation of Akt and ERK. It 
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may explain the synergistic effect observed in the proliferation assay as mentioned 
above.  
SDAHER3-D5A1-IRDye800 conjugate as fluorescence imaging probe for ErbB3-
expressing cancers 
 SDAHER3-D5A1-IRDye800 was conjugated, purified and quantified before 
injecting to the ASPC1 or PANC1 mouse xenograft mice. Non-blocking and blocking of 
unlabeled SDAHER3-D5A1 were used to eliminate the signals from non-specific binding. 
In ErbB3 expression ASPC1 tumors, SDAHER3-D5A1-IRDye800 showed an increase in 
tumor:muscle ratio during the time course in the experiment. It may due to the 
accumulation in the circulation after injection. After the blocking, the fluorescence signal 
decreased a lot. On the other hand, a blocking treatment did not decrease the 
fluorescence signal, and the tumor:muscle ratio did not increase in PANC1 mouse 
xenograft model. The result suggested that SDAHER3-D5A1-IRDye800 targeted the 
ASPC1 tumors in mice. The conjugated molecule may be useful for imaging purpose.  
58 
 
Discussion 
 Although the results listed in this chapter are mostly from preliminary data, all the 
experiments showed promising results in translate SDAHER3-D5A1 into theranostic 
applications. Targeted delivery with nanoparticles may be useful in reducing the 
cytotoxicity and overcome the drug resistance72,86. Such proof of concept can be easily 
validated by conjugating the targeting ligand with gold nanoparticles and use 
nanoparticle-mediated hyperthermia for cancer treatment87. A similar work was 
presented by the previous work from our lab53. SDAHER3-D5A1 is able to carry the 
conjugated nanoparticles and selectively target the ErbB3-expressing cells. It is 
possible to expand this application to many other targeted nanoparticle delivery systems 
with toxins or other therapeutic agents72. Many of the ErbB3 targeting antibodies in 
clinical trials are used together with other antibodies or small molecule drugs37. Thus, 
Lapatinib was selected to treat cancer cells together with SDAHER3-D5A1. As expected, 
treatment of a combination of the two agents demonstrated better inhibition effect than 
using the agents separately in the ErbB2 and ErbB3 positive cell line. The western blot 
analysis helped understand the mechanism of the inhibition. SDAHER3-D5A1 is able to 
inhibit the ligand-induced activation of the downstream pathways, including the 
phosphorylation of ErbB3, Akt and ERK by binding to the extracellular domain of ErbB3. 
Lapatinib can only partially inhibit the activation of Akt and ERK through inhibiting the 
kinase activity of EGFR and ErbB2. Thus, a combination of the two agents showed a 
addition effect towards the proliferation of the cancer cells, especially to those with both 
ErbB2 and ErbB3 overexpressed. The next step would be using mouse xenograft 
models to test whether SDAHER3-D5A1 and the combination therapy can induce tumor 
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regression as described in similar works with anti-ErbB3 antibodies61,88. In order to 
validate the binding ability of SDAHER3-D5A1 in mouse xenograft models, as well as its 
potential in live animal imaging, SDAHER3-D5A1 was conjugated with IRDye800CW. The 
result suggested that SDAHER3-D5A1-IRDye800 conjugate targeted the ErbB3-
overexpressed ASPC1 tumor and accumulated in tumor through the course of time. A 
blocking experiment with excessive amount of unlabeled SDAHER3-D5A1 confirmed that 
non-specific binding did not contribute to the entire observed fluorescence signal. In 
contrast, PANC1 tumor did not have any similar properties as ASPC1 after the injection 
of the conjugate, and the blocking did not show any effect in decrease the fluorescence 
signals. However, PANC1 mouse xenograft models had a higher tumor:muscle ratio 
after injection. It may due to the vascular permeability of different tumors89. The 
fluorescence signals from IRDye800 may also be influenced by the tumor position, size 
and other factors. Thus, it is difficult to directly quantify and compare the imaging results 
among different mice and types of tumors. In some reported experiments, PET imaging 
was used with several of isotopes, such as (111)In78, (89)Zr80, (68)Ga90 and 
99mTc(CO)391, which provides more accurate results for quantification.   
60 
 
Figure 4.1 Internalization assay confirmed that SDAHER3-D5A1 bound to ErbB3 
receptors and got internalized after 2 hours incubation at 37 °C 
The labeled SDAHER3-D5A1 selectively binds to ErbB3-positive ASPC1 cells and after 
incubation at 37 °C for 2 hours, the labeled SDAHER3-D5A1 internalized into the cells. 
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Figure 4.2 Hyperthermia treatment using SDAHER3-D5A1-AuNP 
 
The cells were incubated with 200 nM SDAHER3-D5A1-AuNP at 37 °C for 2 hours to 
promote internalization. NIR laser (800 nm, 1W) was used for 8 minutes. Live/Dead cell 
staining kit was used to visualize living (green) and dead cells (red). Only ErbB3-
positive MCF7 cells responded to hyperthermia treatment and cell death was observed 
near the center of the laser treatment.   
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Figure 4.3 Proliferation of MCF7 cells, treated with 500 nM SDAHER3-D5A1, 5 μM 
Lapatinib, and a combination of protein and the drug 
MCF7 is an ErbB3-overexpressed cell line but with low expression of ErbB2. The 
addition of 500nM SDAHER3-D5A1 inhibited the NRG1 stimulated proliferation. 5 μM 
Lapatinib did not inhibit the proliferation significantly. A combination of SDAHER3-D5A1 
and Lapatinib may show some further inhibition of the cell proliferation, however, the 
difference is not statistically significant.  
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Figure 4.4 Proliferation of BT474 cells, treated with 500 nM SDAHER3-D5A1, 5 μM 
Lapatinib (positive control), 25 nM Lapatinib and a combination of protein and the 
drug 
BT474 is an ErbB2 and ErbB3-overexpressed cell line. The addition of 500nM SDAHER3-
D5A1 inhibited the NRG1 stimulated proliferation. 5 μM Lapatinib almost completely 
inhibit the growth of the cell. 25 nM Lapatinib did not show good inhibition to the ligand-
induced proliferation, but in combination with SDAHER3-D5A1, the inhibition effect was 
greatly improved.  
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Figure 4.5 Proliferation of ErbB3-negative MDA-MB-231 cells, treated with 500 nM 
SDAHER3-D5A1, 5 μM Lapatinib (positive control), 25 nM Lapatinib and a 
combination of protein and the drug 
MDA-MB-231 is with no/minimum ErbB3 expression. It does not response to NRG1 
stimulation and SDAHER3-D5A1 showed on effect on proliferation. With 3 uM Lapatinib, 
the cell growth was slightly inhibited and an combination of the protein and drug did not 
show difference with significance.  
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Figure 4.6 Western blot analysis of SDAHER3-D5A1 and its effect on the 
downstream pathways of MCF7 cells 
After 10 nM NRG1 stimulation, ErbB3, Akt and ERK were activated. Neither SDAHER3-
D5A1 nor Lapatinib could not inhibit phosphorylation of ErbB3, Akt and ERK by itself. 
However, a combination of the two demonstrated better inhibition effect on the NRG1-
induced stimulation.  
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Figure 4.7 Live imaging results from ASPC1 mouse xenograft models with 
SDAHER3-D5A1-IRDye800, for 1 hour, 4 hours and 24 hours after injection. 
After injection, the major signals came from the tumor, liver and the kidney. The signals 
from the blood and tissues were gradually cleared. After 24 hours, the tumor region still 
maintained relatively high signals, which suggested the SDAHER3-D5A1-IRDye800 
bound to ASPC1 tumor. 
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Figure 4.8 The change in tumor:muscle ratio after injection of SDAHER3-D5A1-
IRDye800 or SDAHER3-D5A1-IRDye800 with 20 fold excess of unlabeled SDAHER3-
D5A1 (as blocking agent) at 1 hours, 4 hours, 24 hours and 48 hours in ASPC1 
mouse xenograft model (Non-blocking: N = 7, Blocking: N =2) 
The tumor:muscle ratio from the ASPC1 tumor increases over the time course. With 
blocking of unlabeled SDAHER3-D5A1 proteins, the tumor:muscle ratio decreased 
significantly, which suggested the SDAHER3-D5A1 bind to tumor with specificity in mouse 
xenograft models.  
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Figure 4.9 The change in tumor:muscle ratio after injection of SDAHER3-D5A1-
IRDye800 or SDAHER3-D5A1-IRDye800 with x 20 fold excess of unlabeled SDAHER3-
D5A1 (as blocking agent) at 1 hours, 4 hours, 24 hours and 48 hours in PANC1 
mouse xenograft model (Non-blocking: N = 3, Blocking: N = 2) 
The tumor:muscle ratio from the PANC1 tumor increases over the time course. With 
blocking of unlabeled SDAHER3-D5A1 proteins, the tumor:muscle ratio did not decrease, 
instead, all tumors with pre-blocking showed slightly increased in signals. No 
observation of increased tumor:muscle ratio during the experiment as observed in 
ASPC1 mouse xenograft model. 
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CHAPTER 5 
General discussion 
 
In the present study, novel FN3-based SDAs were selected through directed 
selection with mRNA display against ErbB3. In a similar study, Kronqvist and his 
colleagues identified several affibodies that bind to ErbB3 with nano and sub-nanomolar 
binding affinity through phage display57. In comparison of reported affibody and SDAs 
selected in our study, they all have similar binding affinity. Affibodies also have some 
cellular effects56. However, due to the limitation of phage display, the size of the affibody 
limited its application as therapeutic agents. So far, affibody has only been used as 
imaging agent for diagnosis in clinical trial92; while FN3-based protein Pegdinetanib has 
been in phase II clinical trials for treating glioblastoma, non-small cell lung cancer and 
colorectal cancer93,94. The major efforts for the ErbB3 targeting affibodies were 
contributed to the live animal imaging81,91. In contrast to the affibodies study, this study 
also focuses on the therapeutic effect of selected SDAHER3s. To improve the biophysical 
property and affinity, the two selected SDAHER3s (SDAHER3-A1 and SDAHER3-D5) were 
engineered into one biparatopic molecule (SDAHER3-D5A1). The Cysteine residue at the 
C-terminus made the labeling and targeting easier by reaction and modification. The 
biparatopic molecule has picomolar affinity in vitro and selectively bind to the 
extracellular domain ErbB3 both in vitro and on cell surface. Therefore, the molecule is 
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promising for theranostic purpose. In the experiments, SDAHER3-D5A1 demonstrated its 
capabilities in targeted delivery, addition effect with other drugs, as well as imaging for 
diagnosis. However, due to the limitations in experiments and time, this study did not 
explore the mechanism of the binding by crystal structures as Lee did for her study on 
an anti-ErbB3 antibody with the extracellular domain of ErbB395. The proliferation 
assays and western blot analysis shed some lights on the mechanisms. It is 
hypothesized that the selected SDAHER3s may be able to block the ligand binding of 
NRG1 and disrupt the dimerization of ErbB2 and ErbB3 (preliminary co-IP data was not 
shown here). It would be interesting to visualize how the selected SDAHER3s interacts 
with the extracellular domain of ErbB3 and confirm the mechanisms of the molecule in 
disrupting the ligand-induced activation of downstream signaling pathways. For targeted 
delivery system, SDAHER3-D5A1-Cys may be useful for targeted delivery of polymeric 
nanoparticles such as PLGA nanoparticles with toxins or small molecule drugs 
inside96,97. For therapeutic treatment, many of the anti-ErbB3 antibodies were used in 
combination with other antibodies/drugs in treating breast cancers or NSCLC. In clinical 
trials, MM-121 and trastuzumab were used together to treat trastuzumab-resistant 
patients98. MM-121 enhanced the effect of paclitaxel in ErbB2-overexpressing breast 
cancer99.  MM-121 was combined with Cetuximab and inhibited tumor growth of head 
and neck cancers100. Thus, many other combinations of SDAHER3-D5A1 and therapeutic 
agents can be tested with different types of ErbB3-overexpressing cancer cell lines. 
Meanwhile, mouse xenograft models are necessary to validate the cellular effect of 
SDAHER3-D5A1 and the synergistic effect. For small animal imaging, the preliminary 
data showed some promising results. However, IRDye800 and current xenograft limited 
71 
 
the quality and reliability of the data. The PET imaging may be more helpful in quantify 
the efficiency and other mouse xenograft models should be tested to improve the 
results101. Besides biparatopic molecules, the future study may include the development 
of bispecific molecules. MEHD7945A is a bispecific antibody that targeting EGFR and 
ErbB3 with high affinity102. It showed anti-tumor effect with radiation and is currently in 
clinical trials103. Hackel and his colleagues identified an FN3-based protein that binds to 
EGFR through yeast display104. Therefore, it should be straightforward to combine the 
selected SDAHER3s with this FN3-based EGFR binder through the similar approach for 
SDAHER3-D5A1 construction. Other potential targets may be insulin growth factor 
(IGF1R)105, VEGFR2106, TNF-α107 and Estrogen Receptor α108, all of which have FN3-
based protein binders. Overall, the flexibility of FN3 domain in protein engineering and 
high affinity to ErbB3 make SDAHER3-D5A1 a good candidate for theranostic 
development.   
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